Publications

ZAAPS Program results for 2015: An activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries. by Pfaller MA, Mendes RE, Streit JM, Hogan PA and Flamm RK published in J. Antimicrob. Chemother., 2017;72 (11): 3093-3099

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an antimicrobial surveillance program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Flamm RK and Castaneheira M published in J. Glob. Antimicrob. Resist. 2017: 10; 186-194

Telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2014). by Duncan LR, Sader HS, Smart JI, Flamm RK and Mendes RE published in J. Glob. Antimicrob. Resist.2017; 10: 271-276

Activity of dalbavancin tested against gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014 – 2015). by Pfaller MA, Mendes RE, Sader HS, Castanheira M and Flamm RK published in J. Glob. Antimicrob. Resist. 2017; 11: 4-7

In vitro activity of telavancin against clinically important gram-positive pathogens from 69 U.S. medical centers (2015): Potency analysis by U.S. census divisions. by Pfaller MA, Sader HS, Flamm RK, Castanheira M, Smart JI and Mendes RE published in Microb. Drug Resist., 2017; 23 (6): 718-726

Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: Report from an antimicrobial surveillance program (PACTS, 2012-2015). by Shortridge D, Castanheira M, Pfaller MA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61: e00465

Antimicrobial susceptibility trends among Staphylococcus aureus from United States hospitals: Results from 7 years of the ceftaroline (AWARE) surveillance program (2010-2016). by Sader HS, Mendes RE, Streit JM and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (9): e01043

Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and Echinocandin-resistant strains of Candida spp. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Antimicrob. Agents Chemother. 2017; 61 (8): e00161

In vitro activity of linezolid against clinically important gram-positive cocci in the United States: A 5-year summary of in vitro activity and resistance mechanisms from the LEADER Surveillance Program (2011-2015). by Pfaller MA, Mendes RE, Streit JM, Hogan PA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (7): e00609

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. by Mitton-Fry MJ, Brickner SJ, Hamel JC, Barham R, Brennan L, Casavant JM, Ding X, Finegan S, Hardink J, Hoang T, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Subramanyam C, Plotkin M, Reilly U, Schafer J, Stone GG, Uccello DP, Wisialowski T, Yoon K, Zaniewski R and Zook C published in Bioorg. Med. Chem. Lett. 2017; 27 (15): 3353-3358

In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. aureus isolates from two Phase 3 Studies of acute bacterial skin and skin structure infections (ABSSSI). by McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C and Cammarata S published in Antimicrob. Agents Chemother. 2017; 61 (9): e007722017

Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria. by Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE and Sader HS published in Antimicrob. Agents Chemother. 2017; 61 (7): e00468-17

Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. by Castanheira M, Huband MD, Mendes RE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (9): e00567

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary ABSSSI Isolates from the United States (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-4

In Vitro Activity of Telavancin against Staphylococcus aureus Causing Pneumonia or Skin and Skin Structure Infections with Concomitant Bloodstream Infections in United States Hospitals (2012-2016). Lead author: L Duncan, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-141

Antimicrobial Synergistic Effect of a New Anti-Gram-Positive Agent Tested in Combination with a Polymyxin Derivative against Gram-Negative Pathogens, Including ESKAPE Group Organisms. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-23

In Vitro Activity of Plazomicin and Comparator Agents against Urinary Tract Infection Isolates from the United States and Europe. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-10

Emergence of Proteeae Species Isolates Carrying bla_IMP-27-like in United States and Mexico. Lead author: L Deshpande, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Sunday-125

Intrinsic Resistance Mechanisms Detected Among Ceftazidime-Avibactam-Susceptible and -Resistant Pseudomonas aeruginosa Isolates Collected from United States Hospitals (2015). Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA.
#Sunday-166

Antimicrobial Activity of Ceftobiprole When Tested against Isolates from Diabetic Foot Infections (2013-2016). Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-6

Aminoglycoside-Resistance Genes Among 2014-2015 US Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized Isolates. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-9

Antimicrobial Susceptibility Trends among Staphylococcus aureus from US Hospitals: Results from 7 years of the Ceftaroline (AWARE) Surveillance Program (2009-2015). Lead author: H Sader presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-142

Activity of Solithromycin and Comparators against Respiratory Tract Pathogens Collected in the 2016 Global SENTRY Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-7

Antimicrobial Activity of Ceftobiprole When Tested against Contemporary Isolates from US Medical Centers (2016). Lead author: R Flamm, presented at ASM Microbe 2017, New Orleans, Louisiana, USA
# Sunday-12

Updated Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bloodstream Infections in United States and European Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-33

Potentiation of Clarithromycin When Combined with a New Cationic Peptide against Gram-negative Clinical Isolates and Molecular Analysis of Macrolide Resistance Mechanisms by Next-Generation Sequencing. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-162

Synergistic Effect of Novel Gyrase Inhibitor Agents (SPR750 and SPR751) in Combination with a Polymyxin Derivative (SPR741) against Recent Acinetobacter baumannii and Enterobacteriaceae. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-13

In vitro Antibacterial Activity of Omadacycline and Comparators against Key Respiratory, Skin and Skin Structure, and Urinary Tract Pathogens Collected from the United States and Europe during the 2016 SENTRY Antimicrobial Surveillance Program. Lead author: M Huband presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-45

Multilaboratory Broth Microdilution MIC Reproducibility Study for GSK3342830, a Novel Catechol-Cephem. Lead author: P Rhomberg, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-287

Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Pseudomonas aeruginosa, Klebsiella spp., and Escherichia coli Isolates Collected in Asia-Pacific, North and Latin America, and Europe from 2011-2016. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-29

Antimicrobial Activity of Meropenem-WCK 4234 (WCK 5999) against Clinical Isolates of Acinetobacter spp. Collected Worldwide and Stratified by Infection Type. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Saturday-97

Fosfomycin In Vitro Activity against Bacteria with Various Mechanisms of Resistance to Other Antibacterials from US Hospitals. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-61

Evaluation of Fosfomycin Activity When Combined with Selected Antimicrobial Agents and Tested against Bacterial Isolates Using Checkerboard Methods. Lead author: P Rhomberg, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-406

Activity of Fusidic Acid against Recent Clinical Isolates of Staphylococci Collected from United States Hospitals in 2016 as Part of the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-56

In Vitro Activity of LYS228 against Enterobacteriaceae, Including Molecularly Characterized Multidrug-Resistant Isolates. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-293

Fosfomycin Activity When Tested against Gram-Positive and Gram-Negative US Isolates Collected by the SENTRY Antimicrobial Surveillance Program. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-57

Correlation of Reference Agar Dilution MIC Values and Kirby-Bauer Disk Diffusion Testing for Fosfomycin against Gram-Positive and Gram-Negative Bacteria. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-411

Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-414

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates, Including Carbapenem-Resistant and Carbapenemase-Producing Isolates, Collected in United States (US) Hospitals During 2016. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-58

Tedizolid Activity against Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis in United States and European Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-341

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Pseudomonas aeruginosa Isolates with Various Resistant Phenotypes from US Hospitals. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-50

Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2015). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-129

Meropenem-Vaborbactam (Carbavance^TM) MIC and Zone Diameter Quality Control Ranges Using a CLSI M23-A4 Multi-Laboratory Study Design. Lead author: M Huband, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-417

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) When Tested against Bacterial Isolates from Patients Hospitalized with Pneumonia. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-52

Susceptibility of Ceftolozane-Tazobactam against Isolates Collected from Intensive Care Unit Patients in US Hospitals from 2014-2016. Lead author: M Pfaller, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-76

Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-414

Impact of Changes in Growth Medium, Inoculum Density, and Incubation Conditions on the In Vitro Antimicrobial Activity of Plazomicin. Lead author: L Duncan presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-410

In Vitro Activity and Potency of the Novel Oxazolidinone MRX-I Tested against Contemporary Clinical Isolates of Gram-Positive Bacteria. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-343

Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Isolates Harboring β-Lactamase Genes Detected Using Whole Genome Sequencing Analysis. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-57

Oritavancin In Vitro Activity Against a Collection of Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis, in United States and European Hospitals (2012-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-342